Bristol-Myers Squibb(US:BMY) 智通财经网·2025-07-28 23:30Group 1 - Bristol-Myers Squibb (BMY) and Bain Capital announced the formation of a new independent biopharmaceutical company focused on developing therapies for autoimmune diseases [1] - The new company will initially possess five immunology assets acquired from Bristol-Myers Squibb and has secured a $300 million financing commitment primarily from Bain Capital [1] - The research pipeline includes three drugs in clinical trials and two drugs entering early research stages, all targeting mechanisms related to autoimmune diseases [1] Group 2 - Core assets include afimetoran, an oral drug currently in mid-stage clinical trials for systemic lupus erythematosus, and BMS-986322, which has shown positive results in mid-stage trials for plaque psoriasis [1] - According to the collaboration agreement, Bristol-Myers Squibb will retain nearly 20% equity in the new company and will receive royalties and milestone payments based on the development and commercialization success of these assets [1] - The Canadian Pension Plan Investment Board is also participating in this investment [1] Group 3 - Bristol-Myers Squibb is betting on a series of new drugs to compensate for the declining sales of its legacy blockbuster drugs [2] - The company's best-selling cancer immunotherapy drug Opdivo is expected to face pricing pressure before 2030, while its blood thinner Eliquis will face generic competition by 2028 [2] Group 4 - As of the latest update, the company's stock rose by 0.29% in after-hours trading [3]